| Popis: |
Background : Currently, there is a lack of data relating to glycemic parameters and their relationship with C-peptide (CP) and proinsulin (PI) during the honeymoon period in type 1 diabetes mellitus (T1D). The aim of this study was to evaluate glycemic parameters in children with T1D who are in the honeymoon period using intermittently scanned continuous glucose monitoring systems (isCGMS) and to investigate any relationships between CP and PI levels.Methods: The study included 21 children who were in the honeymoon period and 31 children who were not. A cross-sectional, non-randomized study was performed. Demographic, clinical data were collected and 2 week- isCGMS data were retrieved.Results: The Serum CP showed a positive correlation with time-in-range in the honeymoon period (p:0.03), however PI showed no correlations with glycemic parameters in both periods. The Serum CP and PI levels and the PI:CP ratio were significantly higher in the honeymoon group than in the non-honeymoon group. In the non-honeymoon group, the PI level was below 0.1 pmol/L (which is the detectable limit) in only 2 of the 17 cases as compared with none in the honeymoon group. Similarly, only 2 of the 17 children in the non-honeymoon group had CP levels of less than 0.2 nmol / L, although both had detectable PI levels. Overall time-in-range (3.9-10 mmol/L) was significantly high in the honeymoon group. In contrast, the mean sensor glucose levels, time spent in hyperglycemia, and coefficient of variation levels (32.2vs 40.5%) were significantly low in the honeymoon group. Conclusions: While the CP levels did have an effect on glycemic parameters during the honeymoon period, there was no correlation between PI levels and glycemic parameters. In terms of glycemic parameters during the honeymoon period, the CP level had a significant correlation with the TIR value. CP seems to be a useful biochemical tool, while PI was not a sensitive biochemical parameter. Further studies are needed to determine if PI might prove to be a useful parameter in clinical follow-up. |
